Real-world use of selumetinib for adult NF1 with inoperable plexiform neurofibromas

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multicenter observational registry enrolling about 800 adults with NF1 starting selumetinib across roughly 45 sites in China. The study collects real-world data on effectiveness and safety over up to 96 weeks after the first dose, with an enrolment window of about 25 months. Inclusion requires informed consent, age 18 or older, and a diagnosis of NF1 with symptomatic, inoperable PN and at least one additional NF1 diagnostic criterion. Sites are selected for NF1-PN expertise and patient pool, and follow-up continues through the 96-week observation period or until withdrawal, death, or loss to follow-up.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Willing and able to provide written informed consent to participate in the study.
2. Participants must be ≥ 18 years at the time of screening.
3. All participants must have a diagnosis of NF1 with symptomatic, inoperable PN where:

   a)Participants must have PN and at least one other diagnostic criterion for NF1 \[18\]: (i)Six or more café-au-lait spots (\> 5 mm in greatest diameter in pre-pubertal participants or \> 15 mm in greatest diameter in post-pubertal participants) (ii)Freckling in the axillary or inguinal region
   * At least one of the two pigmentary findings (cafe-au-lait macules or freckling) should be bilateral (iii)Two or more iris Lisch nodules identified by slit lamp examination or 2 or more choroidal abnormalities-defined as bright, patchy nodules imaged by optical coherence tomography/near-infrared reflectance imaging (iv)Optic pathway glioma (v)A distinctive osseous lesion such as sphenoid dysplasia, anterolateral bowing of the tibia, or pseudoarthrosis of a long bone
   * Sphenoid wing dysplasia is not a separate criterion in case of an ipsilateral orbital PN.

   (vi)A NF1 heterozygous pathogenic variant with a variant allele fraction of 50% in apparently normal tissue such as white blood cells (vii)A parent with NF1 by the above criteria b)Target PN \[15\] is defined as a PN that is measurable (i.e. a PN of at least 3cm measured in one dimension, which can be seen on at least 3 imaging slices, and has a reasonably well-defined contour), symptomatic, and considered inoperable. Regular MRI/ Contrast-enhanced MRI/DCE-MRI/WB-MRI analysis might be performed on the target PN for volumetric analysis. If multiple PNs are present, the investigator will select the PN that is most clinically relevant (e.g., causing the predominant symptom) as the target PN.

   c)Inoperable is defined as a PN that cannot be completely surgically removed without a risk of substantial morbidity (including significant bleeding or damage to nerves and/or surrounding vital structures) due to encasement of, or close proximity to, vital structures, invasiveness, or high vascularity of the PN; or unacceptable risk from the general anesthetic as assessed by the investigator.

   d)Symptomatic is defined as clinically significant symptoms caused by the PN, as judged by the investigator; symptoms may include, but are not limited to, pain, motor dysfunction, and disfigurement.
4. Have a documented treatment plan or prescription for selumetinib in the medical records as assessed by the investigator, indicating the decision to initiate selumetinib treatment.
5. The first dose of selumetinib is administered within 28 days after ICF.

Exclusion Criteria:

1. Participants with any evidence of a life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion, makes it undesirable for the participants to participate in the study.
2. Participants with a confirmed or suspected malignant glioma or MPNST, or with a prior malignancy or other cancer requiring treatment with chemotherapy or radiation therapy.
3. Inability to undergo MRI and/or contraindication for MRI examinations.
4. Have had prior treatment with a MEKi, Ras or Raf inhibitor.
5. Currently enrolled in any interventional clinical trial at the time of enrolment or initiation of selumetinib.
6. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).
7. Judgment by the investigator that the participant will not be able to adequately understand or consistently complete ePRO instruments.
8. Pregnant or breastfeeding women.
9. Male participants or female participants of childbearing potential who have childbearing plans (currently or within the next 3 months).

Where it's running

• Research site
  Wuhan, China Recruiting
• Research site
  Beijing, China Not yet recruiting
• Research site
  Changchun, China Not yet recruiting
• Research site
  Changsha, China Not yet recruiting
• Research site
  Chengdu, China Not yet recruiting
• Research site
  Chongqing, China Not yet recruiting

Study contacts

• Principal investigator: Zhichao Wang — Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
• Study coordinator: AstraZeneca Clinical Study Information Center
• Email: information.center@astrazeneca.com
• Phone: 1-877-240-9479

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combo therapy with selumetinib and trastuzumab deruxtecan for advanced pancreatic cancer

  This phase 1/2 trial tests whether the combination of selumetinib and DS-8201a (trastuzumab deruxtecan) is safe and whether it can help people with unresectable or metastatic pancreatic ductal adenocarcinoma.

  Recruiting Phase 1/2 National Cancer Institute (NCI) · Pittsburgh, Pennsylvania · NCT07619521

• Testing PAS-004 for adults with Neurofibromatosis Type 1 and plexiform neurofibromas

  This study is testing a new medication called PAS-004 to see if it is safe and helps adults with Neurofibromatosis Type 1 and painful plexiform neurofibromas.

  Recruiting at 5 sites Phase 1 Pasithea Therapeutics Corp. · Birmingham, Alabama and 4 other locations · NCT06961565

• MeK and MDM2 inhibitors in NF1-related tumors

  This study tests a combination of selumetinib and APG-115 in adults and older teens with NF1 who have unresectable or metastatic MPNST or related conditions to see if the treatment is tolerable and helps slow or stop tumor growth.

  Recruiting at 2 sites Phase 1/2 Children's National Research Institute · Washington D.C., District of Columbia and 1 other locations · NCT06735820

• Combination therapy to shrink plexiform neurofibromas in NF1 patients

  This trial tests whether the drugs cabozantinib and selumetinib can be safely given together to see if they help shrink progressive or painful plexiform neurofibromas in adolescents and adults with NF1.

  Recruiting at 8 sites Phase 1 University of Alabama at Birmingham · Birmingham, Alabama and 7 other locations · NCT06502171

• Study on the use of Koselugo for treating Neurofibromatosis 1

  This study is testing how well Koselugo works and how safe it is for people with Neurofibromatosis 1 in everyday treatment settings in South Korea.

  Recruiting at 9 sites AstraZeneca · Busan and 11 other locations · NCT06360406

• Early selumetinib to try to prevent plexiform neurofibromas in young children with NF1

  This trial will see if giving selumetinib to young children with NF1 who are at high risk can prevent or slow the development of plexiform neurofibromas.

  Recruiting at 15 sites Phase 2 University of Alabama at Birmingham · Birmingham, Alabama and 14 other locations · NCT06188741

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.